Regulated information

10 May 2023

Voting rights on 30 April 2023

Declaration relative to the total number of voting rights – April 2023

27 April 2023

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Q1 2023 – Sales announcement

Q1 2023 – Sales presentation

Q1 2023 – Webcast replay

21 April 2023

Combined Shareholders’ Meeting of 31 May 2023

2023 Convening Notice

Voting form

Participate in the Shareholders’ Meeting

2022 Universal registration document – Ipsen

Report of the Board of Directors on the draft resolutions

Preliminary notice to the Meeting published at the BALO on 21 April 2023 – French version

Preliminary notice to the Meeting published at the BALO on 21 April 2023 – Translation for information

Documents availability – 2023 Ipsen Combined Shareholder’s Meeting

Statutory Auditors Report – 2022 Financial Statements

Statutory Auditors Report – 2022 Consolidated Financial Statements

Statutory Auditors’ special report on regulated agreements

Statutory Audit Report – resolutions 2023 CSM (in French)

Total number of voting rights and shares as of 21 April 2023

Convening Notice to the Meeting published at the BALO on 12 May 2023 – French version

Convening Notice to the Meeting published at the BALO on 12 May 2023 – Translation for information

11 April 2023

Voting rights on 31 March 2023

Declaration relative to the total number of voting rights – March 2023 (1)

06 April 2023

Ipsen publishes its 2022 Universal Registration Document

10 March 2023

Voting rights on 28 February 2023

Declaration relative to the total number of voting rights – February 2023

22 February 2023

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

Ipsen – Press Release Announcing Extension of Tender Offer for Albireo

16 February 2023

Ipsen – Consolidated Financial Statements – 2022

IPSEN_2022_CONSOLIDATED FINANCIAL STATEMENTS

10 February 2023

Voting rights on 31 January 2023

Declaration relative to the total number of voting rights and shares – January 2023

09 February 2023

Ipsen presents strong full-year 2022 results and guidance for 2023

FY 2022 – Results announcement

FY 2022 – Results presentation

FY 2022 – Results webcast

09 January 2023

Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

Ipsen to acquire Albireo: announcement

Ipsen to acquire Albireo: presentation

06 January 2023

Voting rights on 31 December 2022

2022 12 31 Ipsen Voting rights

06 January 2023

Ipsen – Half year statement – 2022 12 31

2022 12 31 – IPSEN – PR Half year statement S2 2022 EN

09 December 2022

Voting rights on 30 November 2022

2022 11 30 Ipsen Voting rights

10 November 2022

Voting rights on 31 October 2022

2022 10 31 Ipsen Voting rights

27 October 2022

Ipsen delivers strong sales growth in the first nine months of 2022 and confirms its full-year guidance

YTD 2022 – Sales announcement

YTD 2022 – Sales presentation

YTD 2022 – Webcast

10 October 2022

Voting rights on 30 September 2022

2022 09 30 Ipsen Voting rights

09 September 2022

Voting rights on 31 August 2022

2022 08 31 Ipsen Voting rights

06 September 2022

Share buyback program – Ipsen reporting from 29 August to 02 September 2022 – Detailled

30 August 2022

Share buyback program – Ipsen reporting from 22 to 26 August 2022 – Detailled

23 August 2022

Share buyback program – Ipsen reporting from 15 to 19 August 2022 – Detailed

12 August 2022

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

Ipsen completes acquisition of Epizyme – 12 August 2022

10 August 2022

Voting rights on 31 July 2022

2022 07 31 Ipsen Voting rights

09 August 2022

Share buyback program – Ipsen reporting from 01 to 05 August 2022 – Detailed

05 August 2022

Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022

02 August 2022

Share buyback program – Ipsen reporting from 25 July to 29 July 2022 – Detailed

28 July 2022

Ipsen publishes its 2022 half year financial report

2022 Half-year financial report

28 July 2022

Ipsen delivers strong H1 2022 results and upgrades its full-year guidance

Ipsen – H1 2022 – Results announcement

Ipsen – H1 2022 – Results presentation

Ipsen - H1 2022 - Results webcast

26 July 2022

Share buyback program – Ipsen reporting from 18 July to 22 July 2022 – Detailed

19 July 2022

Share buyback program – Ipsen reporting from 11 July to 15 July 2022 – Detailed

06 July 2022

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

06 July 2022

Ipsen – Half year statement – 2022 06 30

2022 06 30 – IPSEN – PR Half year statement S1 2022 en

05 July 2022

Share buyback program – Ipsen reporting from 27 june to 01 July 2022 – Agrege

Share buyback program – Ipsen reporting from 27 june to 01 July 2022 – Agregé

29 June 2022

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission

Ipsen FDA Priority Review for palovarotene NDA

28 June 2022

Share buyback program – Ipsen reporting from 20 june to 24 June 2022 – Detailed

27 June 2022

Ipsen to acquire Epizyme, expanding its portfolio in oncology

Ipsen to acquire Epizyme expanding its portfolio in oncology

Acquisition of Epizyme

Webcast Acquisition of Epizyme

21 June 2022

Share buyback program – Ipsen reporting from 13 june to 17 June 2022 – Detailed

14 June 2022

Share buyback program – Ipsen reporting from 06 june to 10 June 2022 – Detailed

10 June 2022

Voting rights on 31 May 2022

2022 05 31 Ipsen Voting rights

07 June 2022

Share buyback program – Ipsen reporting from 01 june to 03 June 2022 – Detailed

01 June 2022

Ipsen initiates a share buy-back program to cover its employee free share-allocation plan

27 May 2022

ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types including metastatic non-small cell lung cancer

Ipsen ASCO annual meeting press release ENG FINAL

24 May 2022

Press release post SM

Ipsen – Press release post SM – 24 May 2022

24 May 2022

Description of the share repurchase program

Ipsen – Description of the share repurchase program – 24 May 2022

10 May 2022

Voting rights on 30 April 2022

2022 04 30 Ipsen Voting rights

03 May 2022

Combined Shareholders’ Meeting of 24 May 2022

Documents availability – 2022 Ipsen Combined Shareholder’s Meeting

03 May 2022

Combined Shareholders’ Meeting of 24 May 2022

Documents availability – 2022 Ipsen Combined Shareholder’s Meeting

Convening notice – 2022 Ipsen Combined Shareholders’ Meeting

Voting form – 2022 Ipsen Combined Shareholders’ Meeting

Ipsen voting rights on 15 April 2022 – 2021 Ipsen Combined Shareholder’s Meeting

Auditors report on the resolutions submitted to the 2022 Shareholders’ Meeting (AGA)

03 May 2022

European Commission approves Cabometyx® as a second-line treatment for people living with radioactive iodine-refractory differentiated thyroid cancer

Ipsen_DTC EC approval_ENG

27 April 2022

Ipsen delivers a strong sales performance in the first quarter of 2022

Q1 2022 – Sales announcement

Q1 2022 – Sales presentation

Webcast Q1 2022

15 April 2022

Combined Shareholders’ Meeting of 24 May 2022

Preliminary notice to the Meeting published at the BALO on 15 April 2022 – Translation for information

Preliminary notice to the Meeting published at the BALO on 15 April 2022 – French version only

Report of the Board of Directors on the draft resolutions

Universal-registration-document-2021

14 April 2022

Ipsen publishes its 2021 Universal Registration Document

Universal registration document 2021 – AMF deposit

08 April 2022

Voting rights on 31 March 2022

2022 03 31 Ipsen Voting rights

25 March 2022

Ipsen receives positive CHMP opinion for Cabometyx® in radioactive iodine-refractory differentiated thyroid cancer

Ipsen – DTC CHMP – 25 March 2022

16 March 2022

Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience

Ipsen – Somatuline Autogel Depot Electronic Autoinjector – 16 March 2022

09 March 2022

Voting rights on 28 February 2022

2022 02 28 Ipsen Voting rights

08 March 2022

New patient-reported data demonstrated high satisfaction levels and fewer patients reporting injection-site pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)

Ipsen_ENETS 2022_ENG

16 February 2022

Ipsen – Consolidated Financial Statements – 2021

16 February 2022

Ipsen appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen – Nomination of Catherine Abi Habib EVP Strategy Transformation Digital – 16 February 2022

15 February 2022

Cabometyx® in combination with Opdivo® demonstrated continued survival and quality of life benefits with over two years of follow-up in the Phase III CheckMate -9ER trial

Ipsen – ASCO GU – 15 February 2022

11 February 2022

Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business

FY 2021 – Results announcement

FY 2021 - Results presentation

Webcast replay FY 2021

09 February 2022

Voting rights on 31 January 2022

2022 01 31 Ipsen Voting rights

24 January 2022

Health Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for fibrodysplasia ossificans progressiva

Ipsen – Health Canada approves Ipsen’s Sohonos (palovarotene capsules) – 24 January 2022

21 January 2022

Ipsen nominates Karen Witts as new independent Board member

Ipsen – Nomination of Karen Witts as new independent Board member – 21 January 2022

17 January 2022

Ipsen – Half year statement – 2021 12 31

2021 12 31 – IPSEN – PR Half year statement S2 2021 en

12 January 2022

Voting rights on 31 December 2021

2021 12 31 Ipsen Voting rights

17 December 2021

Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

Ipsen – Genfit Collaboration – 17 December 2021

Ipsen Expanding the scope in Rare Disease

09 December 2021

Voting rights on 30 November 2021

2021 11 30 Ipsen Voting rights

09 November 2021

Voting rights on 31 October 2021

2021 10 31 Ipsen Voting rights

27 October 2021

Ipsen Pledges Ambitious Action on Climate Change

ENG — Press Release – Ipsen Pledge to Climate 27102021_FINAL

21 October 2021

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance

YTD 2021 – Sales announcement

YTD 2021 – Sales presentation

Webcast replay Q3

18 October 2021

Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3

Ipsen – Accent collaboration – 18 October 2021

11 October 2021

Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailed

11 October 2021

Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International

Ipsen – Appointment of Mari Scheiffele – 11 October 2021

08 October 2021

Voting rights on 30 September 2021

2021 09 30 Ipsen Voting rights

18 September 2021

ESMO 2021: Cabometyx® demonstrates sustained 78% reduction in risk of disease progression or death in people living with uncommon form of thyroid cancer

Ipsen – ESMO 2021 – 18 February 2021

10 September 2021

Voting rights on 31 August 2021

2021 08 31 Ipsen Voting rights

31 August 2021

Share buyback program – Ipsen reporting from 23 to 25 August 2021

Share buyback program – Ipsen reporting from 23 to 25 August 2021 – Detailled

17 August 2021

Share buyback program – Ipsen reporting from 16 to 20 August 2021 – Detailed

17 August 2021

Share buyback program – Ipsen reporting from 09 to 13 August 2021 – Detailed

13 August 2021

Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses

Ipsen_Palovarotene NDA withdrawal_13 August

10 August 2021

Voting rights on 31 July 2021

03 August 2021

Share buyback program – Ipsen reporting from 26 to 30 July 2021 – Detailed

03 August 2021

Ipsen publishes its 2021 half year financial report

H1 2021 Half year financial report

02 August 2021

Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders

Ipsen-Exicure collaboration-2 August 2021

29 July 2021

Ipsen delivers strong H1 2021 results and upgrades full-year guidance

H1 2021 – Results announcement

H1 2021 – Results presentation

Webcast replay H1

27 July 2021

Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway

Ipsen-BAKX collaboration-27 July 2021

27 July 2021

Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailed

20 July 2021

Share buyback program – Ipsen reporting from 12 july to 16 July 2021 – Aggregated

13 July 2021

Share buyback program – Ipsen reporting from 05 to 09 July 2021 – Detailed

09 July 2021

Voting rights on 30 June 2021

Ipsen – Voting rights – 2021 06 30

09 July 2021

Ipsen – Half year statement – 2021 06 30

IPSEN – 2021 06 30 – PR Half year statement S1 2021

06 July 2021

Share buyback program – Ipsen reporting from 28 june to 02 July 2021

29 June 2021

Share buyback program – Ipsen reporting from 21 june to 25 june 2021

Share buyback program – Ipsen reporting from 21 june to 25 June 2021 – Detailled

28 June 2021

Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer

Ipsen – Exelixis COSMIC-312 – 28 June 2021

22 June 2021

Share buyback program – Ipsen reporting from 14 june to 18 June 2021

Share-buyback-program-Ipsen-reporting-from-14-june-to-18-June-2021

15 June 2021

Share buyback program – Ipsen reporting from 7 june to 11 June 2021

10 June 2021

Voting rights on 31 May 2021

Ipsen – Voting rights – 2021 05 31

08 June 2021

Share buyback program – Ipsen reporting from 31 May to 4 June 2021

07 June 2021

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen – Exelixis COSMIC-311 ASCO – 7 June 2021

02 June 2021

Ipsen initiates a share buy-back program to cover its performance and employee share plans

01 June 2021

Ipsen announces the launch of an Employee Shareholding Plan

28 May 2021

Ipsen confirms U.S. FDA accepts New Drug Application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)

Ipsen – Palovarotene FDA acceptance – 28 May 2021

27 May 2021

Press release post SM

Ipsen – Press release post SM – 27 May 2021

27 May 2021

Description of the share repurchase program

Ipsen – Description of the share repurchase program – 27 May 2021

12 May 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2021 04 30 Ipsen Voting rights

11 May 2021

Ipsen opts-in to join Exelixis with ongoing development of Cabometyx® for people living with a form of thyroid cancer, based on promising interim results

05 May 2021

Documents availbaility – Combined Shareholders’ Meeting of 27 May 2021

Documents availability – 2021 Ipsen Combined Shareholder’s Meeting

22 April 2021

Ipsen delivers encouraging sales growth in the first quarter of 2021 despite the pandemic, and confirms its full-year guidance

Q1 2021 – Sales announcement

Q1 2021 – Sales presentation

Webcast replay Q1

16 April 2021

Combined Shareholders’ Meeting of 27 May 2021

Preliminary notice to the Meeting published at the BALO on 19 April 2021 – Translation for information

Preliminary notice to the Meeting publsihed at the BALO on 19 April 2021 – French version only

Report of the Board of Directors on the draft resolutions

Universal-registration-document-2020

15 April 2021

Ipsen publishes its 2020 Universal Registration Document

Universal registration document 2020 – AMF deposit

09 April 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2021 03 31 Ipsen Voting rights

31 March 2021

European Commission approves Cabometyx® in combination with Opdivo® as a first-line treatment for patients living with advanced renal cell carcinoma

Ipsen – Cabometyx Opdivo EMA Release – 31 March 2021

12 March 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2021 02 28 Ipsen Voting rights

26 February 2021

Ipsen receives positive CHMP opinion recommending Cabometyx® in combination with Opdivo® as first-line treatment for patients living with advanced renal cell carcinoma

Ipsen – CHMP release – 26 February 2021

12 February 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2021 01 31 Ipsen Voting rights

11 February 2021

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021

FY 2020 – Results announcement

FY 2020 – Results presentation

08 February 2021

New data from pivotal Phase III CheckMate -9ER trial of Cabometyx® in combination with Opdivo® showed significantly improved QoL benefits and sustained superior efficacy versus sunitinib in patients living with aRCC

Ipsen – ASCO GU 2021 – 8 February 2021

05 February 2021

Ipsen to showcase commitment to going beyond traditional outcome measures for patients living with renal cell carcinoma at ASCO GU 2021

Ipsen – ASCO GU 2021 – 5 February 2021

20 January 2021

Ipsen appoints Gwenan White as Executive Vice President, Communications and Public Affairs

Ipsen – Gwenan White nomation – 20 January 2021

19 January 2021

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

20201231 – IPSEN – PR Half-year Statement S2 2020

15 January 2021

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications

Ipsen – TOXINS 2021 – 15 January 2021

12 January 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2020 12 31 Ipsen Voting rights

09 December 2020

Monthly information relative to the total number of voting rights and shares composing the share capital

2020 11 30 Ipsen Voting rights

01 December 2020

Capital Markets Day 2020 – announcement

Capital Market Day 2020 – Announcement

Capital Market Day 2020 - Presentation

01 December 2020

Ipsen highlights new strategic priorities and provides mid-term financial outlook

Capital Market Day 2020 – Announcement

30 November 2020

Ipsen receives FDA Fast Track designation for investigational irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (SCLC)

Ipsen – Onivyde FDA Fast Track – 30 November 2020

10 November 2020

Monthly information relative to the total number of voting rights and shares composing the share capital

2020 10 31 Ipsen Voting rights

27 October 2020

Disclosure of transactions in own shares between 10/19/2020 and 10/20/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 19 October 2020 and 20 October 2020

22 October 2020

Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

YTD 2020 – Sales announcement

YTD 2020 – Sales presentation

20 October 2020

Disclosure of transactions in own shares between 10/12/2020 and 10/16/2020

EN-Web- Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 12 October 2020 and 16 October 2020

13 October 2020

Disclosure of transactions in own shares between 10/05/2020 and 10/09/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 5 October 2020 and 9 October 2020

08 October 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 09 30 Ipsen Voting rights

08 October 2020

Ipsen to present 12 abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress taking place jointly with the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)

Ipsen – WCNR Curtain Raiser – 8 October 2020

06 October 2020

Disclosure of transactions in own shares between 09/28/2020 and 10/02/2020

EN-Web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 28 September 2020 and 2 October 2020

29 September 2020

Disclosure of transactions in own shares between 09/21/2020 and 09/25/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 21 september 2020 and 25 September 2020

25 September 2020

Ipsen appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

Ipsen – ELT appointment – 25 September 2020

22 September 2020

Disclosure of transactions in own shares between 09/14/2020 and 09/18/2020

EN-BW-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 14 september 2020 and 18 September 2020

19 September 2020

ESMO 2020: Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) demonstrates significant survival benefits in patients with advanced renal cell carcinoma in pivotal Phase III CheckMate -9ER trial

Ipsen – ESMO 2020 CheckMate9ER – 19 September 2020

18 September 2020

ESMO 2020: Phase II CLARINET FORTE results show increasing dose frequencies of Somatuline® Autogel® (lanreotide) allows patients with NETs to delay treatment escalation by up to 8.3 months

Ipsen – ESMO 2020 CLARINET FORTE release – 18 September 2020

15 September 2020

Disclosure of transactions in own shares between 07/09/2020 and 11/09/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 7 september 2020 and 11 September 2020

14 September 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 08 31 Ipsen Voting rights

14 September 2020

Ipsen showcases commitment to patient-centric advances in oncology with record number of abstracts to be presented at ESMO 2020 Virtual Congress

Ipsen – ESMO 2020 curtain raiser – 14 September 2020

10 September 2020

Ipsen to present new insights at ASBMR for potential treatment of ultra-rare disease fibrodysplasia ossificans progressiva (FOP), including global Phase III MOVE trial results

Ipsen – ASBMR 2020 – 10 September 2020

08 September 2020

Disclosure of transactions in own shares between 31/08/2020 and 04/09/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 31 August 2020 and 04 September 2020

01 September 2020

Disclosure of transactions in own shares between 24/08/2020 and 28/08/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 24 August 2020 and 28 August 2020

25 August 2020

Disclosure of transactions in own shares between 17/08/2020 and 21/08/2020

EN – web- Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 17 August 2020 and 21 August 2020

25 August 2020

Ipsen to present results from MOVE, the first global Phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting

Ipsen – Global media release MOVE – 25 August 2020

18 August 2020

Disclosure of transactions in own shares between 10/08/2020 and 14/08/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 10 August 2020 and 14 August 2020

17 August 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 07 31 Ipsen Voting rights

11 August 2020

Disclosure of transactions in own shares between 03/08/2020 and 07/08/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 3 August 2020 and 7 August 2020

04 August 2020

Disclosure of transactions in own shares between 27/07/2020 and 31/07/2020

EN – Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 27 July 2020 and 31 July 2020

30 July 2020

Ipsen presents its half year 2020 results and reinstates guidance for full year 2020

H1 2020 – Results annoucement

H1 2020 – Results presentation

28 July 2020

Disclosure of transactions in own shares between 20/07/2020 and 24/07/2020

EN-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 20 July 2020 and 24 July 2020

21 July 2020

Disclosure of transactions in own shares between 13/07/2020 and 17/07/2020

EN – Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 13 July 2020 and 17 July 2020

13 July 2020

Disclosure of transactions in own shares between 06/07/2020 and 10/07/2020

EN-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 6 July 2020 and 10 July 2020

10 July 2020

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

IPSEN – Half-year Statement Liquidity agreement S1 2020

10 July 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 06 30 Ipsen Voting rights

07 July 2020

Disclosure of transactions in own shares between 29/06/2020 and 03/07/2020

EN – Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 29 June 2020 and 3 July 2020

02 July 2020

Ipsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX®) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer

Ipsen – Clinical collaboration to evaluate Cabometyx – 2 July 2020

01 July 2020

Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer

Ipsen – ESMO GI 2020 – 1 July 2020

30 June 2020

Disclosure of transactions in own shares between 22/06/2020 and 26/06/2020

ENGL-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 22 June 2020 and 26 June 2020

23 June 2020

Disclosure of transactions in own shares between 15/06/2020 and 19/06/2020

ENGL – Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 15 June 2020 and 19 June 2020

17 June 2020

Ipsen receives FDA Fast Track designation for liposomal irinotecan (ONIVYDE®) as a first-line combination treatment for metastatic pancreatic cancer

Ipsen – ONIVYDE FDA Fast Track – 17 June 2020

16 June 2020

Disclosure of transactions in own shares between 08/06/2020 and 12/06/2020

ENGL – Achats effectués – Art 5 Règlement Abus de Marché – IPSEN – du 08 June 2020 and 12 June 2020

12 June 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 05 31 Ipsen Voting rights

08 June 2020

Ipsen demonstrates continued commitment to rare diseases with eight abstracts accepted at ENDO 2020 published in the Journal of the Endocrine Society

Ipsen – ENDO 2020 – 8 June 2020

08 June 2020

Ipsen initiates a share buyback program to cover its share allocation plan

29 May 2020

Combined Shareholders’ Meeting of IPSEN S.A. held on 29 May 2020

PR Post Shareholders’ Meeting IPSEN 29 May 2020

29 May 2020

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 29 May 2020

Description of the share repurchase program proposed to the 2020 SM

28 May 2020

Ipsen appoints David Loew as Chief Executive Officer

Ipsen – David Loew CEO appointment – 28 May 2020

23 May 2020

New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence

Ipsen – Carenity 2020 – 23 May 2020

Ipsen – Carenity inforgraphic – 23 May 2020

Ipsen – Carenity Cervical Dystonia inforgraphic – 23 May 2020

19 May 2020

Ipsen announces publication of first matching-adjusted indirect comparison of Cabometyx® (cabozantinib) versus regorafenib in advanced hepatocellular carcinoma in Advances in Therapy

Ipsen – MAIC – 19 May 2020

07 May 2020

20 April 2020

Ipsen announces positive topline results from pivotal Phase III CheckMate -9ER trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) in previously untreated advanced renal cell carcinoma

Ipsen – CheckMate9ER – 20 April 2020

16 April 2020

24 January 2020

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria

Ipsen – Palovarotene – 24 January 2020

17 January 2020

Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy

Ipsen – Dysport – 6 January 2020

20 December 2019

16 October 2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

2019 09 30 Ipsen Voting rights

16 October 2019

Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)

Download

26 September 2019

Ipsen showcases studies at the ESMO 2019 Congress highlighting progress in new approaches for difficult-to-treat cancers

23 September 2019

Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis

20 September 2019

Ipsen to present new data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)

Ipsen ILCA MAIC Press Release_EN

16 September 2019

Information regarding the total number of voting rights and shares

2019/08/31 Ipsen Voting rights

08 September 2019

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

SEPT19_Ipsen Onivyde SCLC World Lung Press Release FINAL_EN

13 August 2019

Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019

H1 2019 – Results announcement

H1 2019 – Results presentation

23 July 2019

Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer

190705_Ipsen Onivyde 1st Line World GI Data Presentation Press Release ENGLISH FINAL

02 July 2019

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 28 May 2019

Download

24 May 2019

New investigational clinical data for Ipsen’s oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting

190522-Ipsen-Oncology-ASCO-Curtain-Raiser

14 May 2019

Ipsen to host an Investor Day to highlight its innovative R&D pipeline and provide financial outlook for 2022

Press release

Ipsen -Investor-Day-2019

13 May 2019

18 April 2019

Ipsen to Present Improvements to Somatuline® Autogel® Pre-filled Syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

ENG-Ipsen_ENETS_Abstract_FINAL

28 February 2019

Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

ENG-Ipsen_ENETS_CR_FINAL

25 February 2019

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Ipsen-to-acquire-Clementia-Final

Ipsen-to-acquire-Clementia1

20 February 2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

2019-01-31-Ipsen-Voting-rights

14 February 2019

Ipsen delivers strong 2018 results and expects continued sales and profit growth in 2019

FY 2018 – Results announcement

FY 2018 – Results presentation

29 January 2019

Exelixis and Ipsen initiate phase 3 pivotal trial (COSMIC-312) of cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma

20 November 2018

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)

15 November 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib

13 November 2018

Information regarding the total number of voting rights and shares

25 October 2018

Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance

YTD 2018 – Sales announcement

YTD 2018 – Sales presentation

16 October 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

21 September 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

18 September 2018

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018

HY 2018 – Results announcement

HY 2018 – Results presentation

24 July 2018

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 30 May 2018

29 May 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

09 May 2018

Information regarding the total number of voting rights and shares

26 April 2018

Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates

Q1 2018 – Sales announcement

Q1 2018 – Sales presentation

28 March 2018

Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).

28 March 2018

Information regarding the total number of voting rights and shares

26 March 2018

Ipsen publishes its 2017 Registration Document

23 March 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

13 March 2018

Ipsen delivers strong 2017 results with 21.1% sales growth and Core operating margin increase of 3.4 points and expects significant further growth in sales and margin in 2018

FY 2017 – Results announcement

FY 2017 – Results presentation

14 February 2018

Information regarding the total number of voting rights and shares

07 February 2018

Ipsen announces eight oral presentations from its Neurosciences portfolio at the 10th World Congress for Neurorehabilitation (WCNR)

29 January 2018

Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma

12 January 2018

Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticity

14 November 2017

Information regarding the total number of voting rights and shares

26 October 2017

Ipsen delivers strong sales growth of 22.6% for the third quarter of 2017 and confirms full year guidance

YTD 2017 – Sales announcement

16 October 2017

Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

11 October 2017

Information regarding the total number of voting rights and shares

19 September 2017

Ipsen receives approval from European Commission for Xermelo® (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

18 September 2017

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

12 September 2017

Information regarding the total number of voting rights and shares

09 September 2017

Ipsen and Exelixis announce results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma at ESMO 2017

08 September 2017

Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults

04 September 2017

Ipsen announces 16 abstract presentations of oncology portfolio at European Society of Medical Oncology congress

16 August 2017

Exelixis submits U.S. supplemental new drug application for Cabometyx^®(Cabozantinib) for the treatment of previously untreated advanced kidney cancer

15 August 2017

25 July 2017

Disclosure of transactions in own shares between 17-07-2017 and 21-07-2017

21 July 2017

Ipsen receives positive CHMP opinion for approval of Xermelo® (telotristat ethyl), for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

18 July 2017

Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETY or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma.

10 July 2017

Disclosure of transactions in own shares between 03-07-2017 and 07-07-2017

04 July 2017

Disclosure of transactions in own shares between 26-06-2017 and 30-06-2017

03 July 2017

Somatuline® Autogel® 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors

30 June 2017

Ipsen announces co-promotion agreement with Saol Therapeutics to promote Dysport® (abobotulinumtoxinA) in the United States

27 June 2017

Disclosure of transactions in own shares between 19-06-2017 and 23-06-2017

21 June 2017

Disclosure of transactions in own shares between 12-06-2017 and 16-06-2017

19 June 2017

Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

16 June 2017

Description of the regulatory framework of the share repurchase program proposed to the Combined Shareholders’ Meeting of 7 June 2017

IPSEN-Descriptif-programme-de-rachat-dactions-EN

11 May 2017

Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals

28 March 2017

The Ipsen Group publishes its 2016 Registration Document

13 March 2017

Ipsen announces MHRA approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer

09 March 2017

Ipsen announces data presentations of lanreotide (Somatuline® Autogel®), telotristat ethyl and the investigational compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 conference

02 March 2017

Ipsen appoints Benoit Hennion as Executive Vice President and President, Primary Care

01 March 2017

Ipsen’s Partner Lexicon Pharmaceuticals Announces That FDA Approves Lexicon Drug Xermelo™ (Telotristat ethyl) 250 mg as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors.

27 February 2017

Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

23 February 2017

Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017

FY 2016 – Results announcement

FY 2016 – Results presentation

13 February 2017

Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada

20 December 2016

The 2016 Georges Mathé Prize recognizes research on the immunological determinants of the response to breast cancer treatment

30205349966_1ac8f6f57f_k.jpg

18 October 2016

Disclosure of transactions in own shares between 10-10-2016 and 14-10-2016

11 October 2016

Disclosure of transactions in own shares between 03-10-2016 and 07-10-2016

10 October 2016

Ipsen and its partner Exelixis announce positive results from phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma presented at the European Society for Medical Oncology (ESMO) 2016 congress

10 October 2016

Information regarding the total number of voting rights and shares

07 October 2016

Ipsens’ partner, Exelixis, announced phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors

04 October 2016

Disclosure of transactions in own shares between 26-09-2016 and 30-09-2016

27 September 2016

Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl* at the European Society for Medical Oncology (ESMO) 2016 congress

27 September 2016

Disclosure of transactions in own shares between 19-09-2016 and 23-09-2016

20 September 2016

Disclosure of transactions in own shares between 12-09-2016 and 16-09-2016

14 September 2016

European Commission approves Ipsen’s Cabometyx™ (cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

13 September 2016

Ipsen Announces FDA Approval of Dysport^® (abobotulinumtoxinA) for injection for the treatment of Lower Limb Spasticity in children aged two and older.

28 July 2016

Supplemental Application Filed for Somatuline^®in Japan for Additional Indication of Neuroendocrine Tumors

28 July 2016

Ipsen’s First Half 2016 Results

H1 2016 – Results announcement

H1 2016 – Results presentation

26 July 2016

Disclosure of transactions in own shares between 18-07-2016 and 22-07-2016

22 July 2016

Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

19 July 2016

Disclosure of transactions in own shares between 11-07-2016 and 15-07-2016

18 July 2016

Ipsen announces the acceptance by the European Medicines Agency of the marketing authorization application for telotristat etiprate to treat carcinoid syndrome caused by neuroendocrine tumors, in combination with somatostatin analogues

12 July 2016

Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX™ (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting

05 June 2016

The Ipsen Group launches an employee shareholding plan

04 June 2016

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

31 May 2016

Combined Shareholders’ Meeting of 31 May 2016

31 May 2016

Eugenia Litz is appointed as Vice President Investor Relations of Ipsen

30 May 2016

Ipsen’s partner, Lexicon, announced FDA Priority Review of new drug application for telotristat etiprate for the treatment of carcinoid syndrome

26 May 2016

Description of the regulatory framework of the share repurchase program proposed to the Combined Shareholders’ Meeting of 31 May 2016

IPSEN-Descriptif-programme-de-rachat-dactions-EN

22 May 2016

Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma

16 May 2016

Ipsen is pleased to announce that its partner Exelixis obtained FDA Approval of CABOMETYX™ (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy

07 April 2016

Information regarding the total number of voting rights and shares

04 April 2016

Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen’s drug discovery

30 March 2016

Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy Cabozantinib in regions outside the United States, Canada and Japan

01 March 2016

Ipsen’s 2015 results and 2016 financial objectives

FY 2015 – Results announcement

FY 2015 – Results presentation

16 February 2016

Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport^® (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy

07 January 2016

Information regarding the total number of voting rights and shares

05 January 2016

Ipsen and Galderma expand current distribution agreement for Dysport^® in aesthetic indications to some key Asia-Pacific territories

03 January 2016

Ipsen’s partner Lexicon announced that Telotristat Etiprate had achieved positive top-line results in second phase 3 clinical trial

29 November 2015

Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA for the treatment of non-muscle invasive bladder cancer in major ex-United States territories

25 October 2015

Disclosure of transactions in own shares between 19-10-2015 and 23-10-2015

25 October 2015

Ipsen and EpiVax collaborate to produce next generation botulinum toxins

21 October 2015

Ipsen presents additional results from a Phase III clinical trial of the investigational use of Dysport® in children with spastic equinus foot deformity due to cerebral palsy

18 October 2015

Disclosure of transactions in own shares between 12-10-2015 and 16-10-2015

18 October 2015

Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotristat etiprate was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.

11 October 2015

Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat etiprate reduces the average number of daily bowel movements in patients with carcinoid syndrome not adequately controlled by somatostatin analogues.

27 September 2015

Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showing efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with upper limb spasticity (ULS)

30 August 2015

Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs

30 July 2015

Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States

06 July 2015

Ipsen initiates a share buyback program Shares will be cancelled to compensate dilution resulting from its free share plans

01 June 2015

Ipsen strengthens its presence in the oncology field with the acquisition of OctreoPharm Sciences, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours

06 May 2015

Information regarding the total number of voting rights and shares

04 May 2015

Description of the regulatory framework of the share repurchase program proposed to the Combined Shareholders’ Meeting of 27 May 2015

IPSEN-Descriptif-programme-de-rachat-dactions-EN

28 April 2015

Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year

15 April 2015

Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer

07 April 2015

Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors

07 April 2015

Information regarding the total number of voting rights and shares

31 March 2015

Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence

31 March 2015

Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults

06 January 2015

Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors

11 December 2014

Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen

08 December 2014

Information regarding the total number of voting rights and shares

27 November 2014

Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients

19 November 2014

Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA

17 November 2014

Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients

06 October 2014

Information regarding the total number of voting rights and shares

01 October 2014

Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities

26 September 2014

Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress

03 September 2014

Information regarding the total number of voting rights and shares

31 August 2014

Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe

28 August 2014

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

10 July 2014

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe

07 July 2014

Information regarding the total number of voting rights and shares

30 June 2014

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

04 June 2014

Ordinary Shareholders’ Meeting of 4 June 2014

1 – Preliminary notice to the Meeting – published in the French BALO (French only) – AGM 4 june 2014

2 – Information voting rights-shares – AGM 4 june 2014

3 – Shareholders’ meeting notice – published in the French BALO (French only) – AGM 4 june 2014

5 – Voting or proxy form – AGM 4 june 2014

6 – Availability and consultation of preparatory documentation for the AGM – AGM 4 june 2014

7 – Registration Document 2013 – AGM 4 june 2014

10 – Press Release post AGM – AGM 4 june 2014

04 June 2014

Description of the regulatory framework of the share repurchase program proposed to the Ordinary Shareholders’ Meeting of 4 June 2014

27 April 2014

Registration Document 2013

11 April 2014

Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul

10 April 2014

The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer”, attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research

06 April 2014

Information regarding the total number of voting rights and shares

19 March 2014

Ipsen announces that its controlling shareholder, Mayroy, sold approximately 7% of Ipsen’s share capital via private placement

17 March 2014

Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO)

06 March 2014

Information regarding the total number of voting rights and shares

27 February 2014

Ipsen’s 2013 results and 2014 financial objectives

06 February 2014

Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer

06 February 2014

Information regarding the total number of voting rights and shares

05 February 2014

Disclosure of transactions in own shares between 30-01-2014 and 03-02-2014

04 February 2014

Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW

29 January 2014

Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET 1 patients with carcinoid syndrome met its primary endpoint

14 January 2014

Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport ® in the treatment of Adults suffering from Upper Limb Spasticity

11 December 2013

The 22nd Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen has been awarded to Jean Decety (University of Chicago, Chicago, USA)

19 November 2013

PeptiDream and Ipsen expand the scope of their collaboration for discovery of peptide drugs to treat serious endocrinologic disease

01 October 2013

New organization project and composition of the Executive Committee to accelerate the implementation of Ipsen’s strategy

27 September 2013

Ipsen announces that results from CLARINET® Phase III clinical trial presented at the 2013 European Cancer Congress showed the antiproliferative effect of Somatuline® (lanreotide) 120 mg injection in the treatment of non-functioning gastroentero and pancreatic neuroendocrine tumors (“GEP-NETs”)

25 September 2013

Ipsen to relocate US R&D activities to Cambridge, MA in 2014

16 September 2013

Ipsen announces positive top line results from phase III ELECT® study of Somatuline® in the control of symptoms in NET patients with a history of carcinoid syndrome

08 September 2013

Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology

14 July 2013

Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases

10 July 2013

Ipsen announces positive results from phase III CLARINET study of Somatuline® Autogel® 120mg in gastrointestinal and pancreatic neuroendocrine tumors (“GEP-NETs”)

08 July 2013

Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer

24 April 2013

Ipsen expects Increlex® supply interruption due to supplier manufacturing issues

24 April 2013

Description of the share repurchase program proposed to the Combined Shareholders’ Meeting of 31 May 2013

23 April 2013

Combined Shareholders’ Meeting of Ipsen on 31 May 2013: Proposals of renewal of the terms of office of two Directors and appointment of a new Director

09 April 2013

Pepti Dream and Ipsen enter into a collaboration for advancing drug discovery efforts for peptides to treat serious disease

08 April 2013

Eziclen® / Izinova® a new product for bowel cleansing successfully completed European decentralised registration procedure

05 February 2013

Ipsen and Inspiration Biopharmaceuticals enter into an Asset Purchase Agreement with Cangene Corporation on IB1001

23 January 2013

Ipsen and Inspiration Biopharmaceuticals enter into an Asset Purchase Agreement with Baxter International on OBI-1

16 January 2013

Teijin Pharma to launch Ipsen’s Somatuline® subcutaneous injection in the treatment of acromegaly and pituitary gigantism in Japan

06 January 2013

Information regarding the total number of voting rights and shares

02 January 2013

Ipsen’s corporate agenda for 2013

17 December 2012

Oncodesign and the Laboratory for Neurobiology and Gene Therapy at the KU Leuven enter into a research collaboration for advancing drug discovery efforts with Ipsen in Parkinson’s disease

09 December 2012

Ipsen and Inspiration Biopharmaceuticals announce that OBI-1 has received Fast Track designation from FDA for acquired hemophilia A

08 November 2012

Ipsen’s partner Inspiration Biopharmaceuticals announces hold of phase III clinical trials evaluating IB1001 for the treatment and prevention of hemophilia B

05 July 2012

Active Biotech’s and Ipsen’s Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer

31 May 2012

Ipsen pursues its development in the United States with the opening of its new commercial headquarters in New Jersey (NJ)

16 April 2012

Ipsen’s partner, Inspiration Biopharmaceuticals, announces US filing of Biologics License Application (BLA) for IB1001, a recombinant factor IX product for the treatment of hemophilia B

05 April 2012

Active Biotech and Ipsen report Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress

06 February 2012

Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson’s disease target

03 January 2012

Ipsen announces its corporate agenda for 2012

05 December 2011

The total number of voting rights and total number of shares

27 November 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces the initiation of the second phase III pivotal clinical study of OBI-1 in congenital hemophilia A with inhibitors

06 November 2011

The total number of voting rights and total number of shares

01 November 2011

Ipsen sells the North American development and marketing rights for Apokyn® to Britannia Pharmaceuticals, achieving a key milestone in the execution of its new North American strategy

26 October 2011

Ipsen’s partner, Inspiration Biopharmaceuticals, announces acceptance of European marketing authorization application for IB1001 for the treatment of hemophilia B

26 September 2011

Ipsen in-licenses from Photocure Hexvix®, the first approved & marketed drug for improved detection of bladder cancer, a key step in the surgical resection

04 September 2011

The total number of voting rights and total number of shares

29 August 2011

Appointments to Ipsen’s Executive Committee: Nathalie Joannes is nominated Executive Vice President, General Counsel and Susheel Surpal is nominated Executive Vice President, Chief Financial Officer

29 August 2011

Ipsen’s half-year 2011 Results

29 August 2011

Inspiration Biopharmaceuticals and Ipsen Expand their Partnership in Preparation for the Commercial Launch of Inspiration’s Hemophilia Pipeline in Europe

02 August 2011

The total number of voting rights and total number of shares

27 July 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces data from OBI-1 pivotal stage program in Hemophilia at 23 rd ISTH congress

11 July 2011

Active Biotech and Ipsen enter into a broad partnership for the co-development and commercialization of TASQ in uro-oncology

07 April 2011

Total number of voting rights and total number of shares

08 March 2011

The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen’s Prior Approval Supplement application

03 March 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces non-inferiority of IB1001, its recombinant factor IX for Hemophilia B

01 February 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces the treatment of the first patient in phase III pivotal study of OBI-1 for acquired hemophilia A

04 November 2010

Ipsen’s Board of Directors announces Jean-Luc Bélingard’s departure and the appointment of Marc de Garidel as new Chairman and CEO

06 October 2010

Total number of voting rights and total number of shares

05 September 2010

Total number of voting rights and total number of shares

02 September 2010

Santhera and Ipsen Enter into Licensing Agreement Santhera and Ipsen Enter into Licensing Agreement in Parkinson’s Disease

30 August 2010

Implementation of a Sponsored Level I American Depositary Receipt (ADR) program: A new step in Ipsen’s development in the United States

27 May 2010

Dicerna Pharmaceuticals and Ipsen enter into an exclusive research collaboration for the development of new therapeutic agents in endocrinology and oncology

23 March 2010

Update on Ipsen’s share capital structure

22 March 2010

GTx and Ipsen expand partnership

14 March 2010

Initiation of two phase II studies with Ipsen’s proprietary BIM 23A760 first-in-class chimeric compound in the treatment of acromegaly and carcinoid syndrome due to neuroendocrine tumors

11 March 2010

Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer

20 January 2010

Ipsen and Inspiration Biopharmaceuticals enter into partnership to create a world leading hemophilia franchise

07 January 2010

Outstanding shares and voting rights

16 December 2009

Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoints in two further head-to-head phase III studies with insulin glargine (Lantus®) and versus placebo in patients with high body mass index (BMI)

16 December 2009

Ipsen’s financial communication nominated to the “2009 Trophy of the Best Investor Relations” of Euronext

13 December 2009

Ipsen establishes optimal biological dose for BN83495 steroid sulphatase (STS) inhibitor in ER-positive metastatic breast cancer

08 December 2009

Ipsen announces its corporate agenda for 2010

03 December 2009

Total number of outstanding shares and voting rights

01 December 2009

Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoints in head-to-head study with sitagliptin (Januvia®) and versus placebo

24 November 2009

Ipsen initiates an Advanced Endometrial Cancer program with BN83495, its first-in-class steroid sulfatase (STS) inhibitor

12 November 2009

Ipsen’s Decapeptyl® 6-month formulation receives marketing authorization in France for the treatment of locally advanced or metastatic prostate cancer

09 November 2009

Ipsen grants Menarini exclusive European licence rights to Adenuric® (febuxostat), its novel treatment for chronic hyperuricaemia in gout

12 October 2009

Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer.

08 October 2009

Appointment of Claude Bertand as Executive Vice President, Chief Scientific Officer of Ipsen. Jacques-Pierre Moreau is appointed Chief Scientific Advisor to the Executive Committee.

20 September 2009

AZZALURE® approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines

14 September 2009

Encouraging preliminary new data available for the treatment of short stature children with low IGF-1 levels.

06 September 2009

Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC-25 inhibitor (IRC-083864 or Debio 0931), an anti-cancer agent. Debio 0931 has the potential to target major human cancers.

27 August 2009

Results of Phase I and Phase IIa clinical studies confirm the inhibitory effect of proprietary Ipsen’s BIM23A760 first-in-class “chimeric” compound on growth hormone, IGF-1 and prolactin levels

05 July 2009

The Health Authorities of 15 European countries give a collective green light to Azzalure® for the treatment of glabellar lines, paving the way for national marketing authorizations

27 January 2009

Ipsen completes the acquisition of Tercica, Inc. in North America, the third of its three steps to globalize its fast growing specialist care business

29 September 2008

FDA’s first-cycle review of Dysport® to be completed by year-end: US launch of Dysport® on track

24 September 2008

Ipsen announces the filing of Decapeptyl® 6-month formulation for the treatment of locally advanced or metastatic prostate cancer in Europe

15 September 2008

Ipsen builds a fully fledged presence in North America, significantly enhancing its geographic footprint, global specialty portfolio and growth profile

03 June 2008

Toremifene citrate 80 mg meets primary and key secondary endpoints in phase III clinical trial in advanced prostate cancer patients on androgen deprivation therapy

20 February 2008

EMEA recommends marketing authorisation of Ipsen’s Adenuric® (febuxostat) for the treatment of chronic hyperuricaemia in gout

14 February 2008

Ipsen grants Galderma exclusive rights to promote and distribute Dysport® in aesthetic medicine and dermatological indications in Brazil, Argentina and Paraguay

05 December 2007

Ipsen and Medicis announce submission of Reloxin® in aesthetics to the FDA

03 December 2007

Seventh Colloque Médecine et Recherche of La Fondation Ipsen in the Endocrinology series: “Hormones and Social Behaviour”

03 December 2007

Ipsen and Debiopharm extend their agreement for the exclusive commercialization of Decapeptyl® (triptorelin pamoate) in Europe and certain other territories

03 October 2007

Phase III clinical trial with 4-month long-acting formulation of triptorelin: Ipsen decides not to perform further administration

05 June 2007

Ipsen grants Galderma exclusive rights to develop, promote and distribute its botulinum toxin type A product for aesthetic indications in Europe and certain other territories

25 February 2007

Appointment of Stéphane Thiroloix as Executive Vice-President, Corporate Development

30 January 2007

Outstanding shares and voting rights

29 January 2007

Agreement between Ipsen and MSD for the co-marketing in France of AdrovanceTM for the treatment of postmenopausal osteoporosis

23 January 2007

Ipsen strikes alliance with the Erasmus University Medical Centre Rotterdam

14 January 2007

FDA accepts for filing a New Drug Application (NDA) for Somatuline® Autogel® – Somatuline® Autogel® now available in Canada

13 December 2006

Type 2 diabetes therapy: Ipsen is currently testing an innovative sustained release formulation of its GLP-1 analogue based on its proprietary drug delivery system technologies

01 June 2006

Choose your location:

Choose a Language